Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phototoxic Potential of Delgocitinib Cream on Healthy Skin
NCT04361136Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Apr 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of delgocitinib in atopic dermatitis (AD) (5 arms), sponsored by LEO Pharma. Primary endpoint: Positive skin reaction at 24 hours or 48 hours after irradiation. Started Apr 2020; status: completed.
02
Drugs
delgocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04361136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361136.